岁月流转，时光飞逝。回首过去一年的工作，经过中医内科学教育部重点实验室全体成员的携手奋进、共同努力，在确保数量稳定的基础上，学术论文发表质量再创新历史新高。

2021年共计发表学术论文137篇，SCI收录60篇，影响因子合计303.404，中科院分区1区8篇，2区15篇，单篇最高影响因子25.391；中文期刊77篇，均为核心期刊。

新的时代迎来新的希望。以成功入选国家中医药传承创新中心项目为契机，全体同仁将继承和发扬优势经验，克服困难不足，满怀信心，以更加清醒的头脑、旺盛的斗志、奋发的姿态和充沛的干劲，向着既定目标持续迈进！

英 文 文 章

1.  心血管病方向

[1]Su, X., X. Zhang^#, W. Liu, X. Yang, N. An,F. Yang, J. Sun,Y. Xing*, and H. Shang*. 2021. Advances in the application of nanotechnology inreducing cardiotoxicity induced by cancer chemotherapy', Semin Cancer Biol.（SCI收录，IF 15.707）.........................................................................................................................1

[2] Jiang, K., Y. Xu,D. Wang, F. Chen, Z. Tu, J. Qian, S. Xu, Y. Xu, J. Hwa, J. Li, H. Shang,and Y. Xiang*. 2022. 'Cardioprotective mechanism ofSGLT2 inhibitor against myocardial infarction is through reduction of autosis',Protein Cell, 13: 336-59.（SCI收录，IF 14.87）.........................................................................................................2

[3] Yang, F., C. Liu^#, X. Liu, X. Pan, X. Li,L. Tian, J. Sun, S. Yang, R. Zhao, N. An, X. Yang, Y. Gao*, and Y. Xing*. 2021. 'Effect of Epidemic IntermittentFasting on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysisof Randomized Controlled Trials', Front Nutr, 8: 669325.（SCI收录，IF 6.576）............................................................................................................3

[4]XiangM, Lu Y, Xin L, Gao J, Shang C, Jiang Z, Lin H, Fang X, Qu Y, Wang Y, Shen Z, Zhao M*, Cui X*. Role of OxidativeStress in Reperfusion following Myocardial Ischemia and Its Treatments. OxidMed Cell Longev 2021, 2021: 6614009.（SCI收录，IF 6.543）.............................................................................................................3

[5]Lv, S., Y. Wang, W. Zhang, and H. Shang*. 2021. 'Trimethylamine oxide: a potential target forheart failure therapy', Heart.（SCI收录，IF 5.994）.........................................................................................................................4

[6]He, Q. Y., X. Y. Yu, Z. Xiao, X. Sun, W. F. Zhu, X. Q.Yi, Q. Chen, J. H. Zhang, S. X. Chen, X. Zhou, H. Y. Nie, H. C. Shang*,and X. F. Chen*. 2021. 'Comparison of the Efficacy of Danhong Injections atDifferent Time-points During the Perioperative Period of Acute MyocardialInfarction: A Systematic Review and Meta-analysis of Randomized ControlledTrials', Front Pharmacol, 12: 643446.（SCI收录，IF 5.81）............................................................................................................................6

[7] Zhang Xiaoyu,ZhaoChen,Zhang^# Houjun,Liu^# Wenjing,Zhang Jingjing,ChenZhao,You Liangzhen,Wu Yuzhuo,Zhou Kehua,Zhang Lijing,Liu Yan*,Chen Jianxin*,ShangHongcai*. Dyspnea Measurement in Acute Heart Failure: A Systematic Reviewand Evidence Map of Randomized Controlled Trials [J]. Frontiers in Medicine,2021,8.（SCI收录，IF5.091）............................................................7

[8] Zhou, Y., T. Yin, M. Shi, M. Chen, X. Wu, K. Wang, I.Cheang, Y. Li, H. Shang*, H. Zhang*,and X. Li*. 2021. 'Nobiletin Attenuates Pathological Cardiac Remodeling afterMyocardial Infarction via Activating PPARgamma and PGC1alpha', PPAR Res, 2021:9947656.（SCI收录，IF 4.964）....................................................................8

[9]Wei, X. H., X. Guo, C.S. Pan, H. Li, Y. C. Cui, L. Yan, J. Y. Fan, J. N. Deng, B. H. Hu, X. Chang, S.Y. He, L. L. Yan, K. Sun, C. S. Wang, and J. Y. Han*. 2021. 'QuantitativeProteomics Reveal That Metabolic Improvement Contributes to theCardioprotective Effect of T89 on Isoproterenol-Induced Cardiac Injury', FrontPhysiol, 12: 653349.（SCI收录，IF 4.566）.........................................................................9

[10] Wang, B., Y. Li^#, X. Hao, J. Yang, X. Han,H. Li, T. Li, D. Wang, Y. Teng, L. Ma, Y. Li, M. Zhao*, and X. Wang*. 2021. 'Comparison of the Clinical Value ofmiRNAs and Conventional Biomarkers in AMI: A Systematic Review', Front Genet,12: 668324.

（SCI收录，IF 4.5)..................................................................................................10

[11]Qiu Ruijin,Han Songjie,Wei Xuxu,ZhongChangming,Li Min,Hu Jiayuan,Wang Pengqian,Zhao Chen,Chen Jing*,Shang Hongcai*. Development of a CoreOutcome Set for the Benefits and Adverse Events of Acute Heart Failure inClinical Trials of Traditional Chinese Medicine and Western Medicine: A StudyProtocol [J]. Frontiers in Medicine,2021,8.（SCI收录，IF4.468）...........................................................11

[12] Wang, P., T. He^#, R. Zheng, Y. Sun, R. Qiu,X. Zhang, Y. Xing*, and H. Shang*.2021. 'Applying cooperative module pair analysis to uncover compatibilitymechanism of Fangjis: An example of Wenxin Keli decoction', J Ethnopharmacol,278: 114214.

（SCI收录，IF 4.36）............................................................................................12

[13] Han, X., T. Li, Y. Li, J. Yang, S. Chen, X. Zhu, B.Wang, W. Cheng, L. Wang, Z. Lu, X. Wu, Y. Jiang, G. Pan, and M. Zhao*.2021. 'Exercise and Circulating Microparticles in Healthy Subjects', JCardiovasc Transl Res, 14: 841-56.（SCI收录，IF 4.132）.................................................................................................................13

[14] Meng, H., W. Cheng, L. Wang, S. Chen, Y. Teng, Z. Lu,Y. Li, and M. Zhao*. 2022.'Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: aSystematic Review of Preclinical In Vivo Studies', J Cardiovasc Transl Res, 15:317-39.（SCI收录，IF 4.13）.......................................................................................14

[15] HouShiqiang,Niu Gengming,Liu Xin,Bourbon Pierre M,Zhang Dongmei,Cui Pengfei,Zhao Kevin,Zhao Dezheng,Zeng Huiyan*. Anovel transcriptional complex on the VE-cadherin promoter regulated thedownregulation of VE-cadherin in the down syndrome candidate region 1 isoform 1L- mediated angiogenesis.[J]. Microvascular research,2021,138.（SCI收录，IF3.514）.......................15

[16] Gao Yijie,Wu Dandan,Jia Dongdong,Guo Qianqian,WangManman,Yang Rui,Zhang Xinyue,Chen Meng,ZhangDongmei*. Hypoxic Stem Cell-derived Extracellular Vesicles for CardiacRepair in Preclinical Animal Models of Myocardial Infarction: aMeta-analysis.[J]. Stem cells and development,2021.（SCI收录，IF3.272）.........................................................................................................................16

[17]Chen, S., X. Wu,T. Li, Y. Li, B. Wang, W. Cheng, Y. Teng, J. Yang, H. Meng, L. Wang, Z. Lu, Y.Jiang, Y. Wang*, and M. Zhao*. 2021.'Atheroprotective Effects and Mechanisms of Postmarketing Chinese PatentFormulas in Atherosclerosis Models: A Systematic Review', Evid Based ComplementAlternat Med, 2021: 4010607.（SCI收录，IF 2.69）..................................................17

[18] Liu, K., M. Lv, X. Ji, L. Lou, B. Nie, J. Zhao, A.Wu*, and M. Zhao. 2021a. 'Advances of Traditional Chinese Medicine RegulatingConnexin43 in the Prevention and Treatment of Myocardial Infarction', EvidBased Complement Alternat Med, 2021: 8583285.（SCI收录，IF 2.629）.............................................................................18

[19] Liu, K., M. Lv, X. Ji, L. Lou, B. Nie, J. Zhao, A.Wu*, and M. Zhao.. 2021b. 'Wenxin Granules Regulate Endoplasmic ReticulumStress Unfolded Protein Response and Improve Ventricular Remodeling on Ratswith Myocardial Infarction', Evid Based Complement Alternat Med, 2021: 7375549.（SCI收录，IF 2.629）......................19

[20] Lou, L., C. Li, J. Wang,A. Wu, T. Zhang, Z. Ma,L. Chai, D. Zhang, Y. Zhao, B. Nie, Q. Jin, H. Chen, and W. J. Liu. 2021.'Yiqi Huoxue preserves heart function by upregulating the Sigma-1 receptor inrats with myocardial infarction', Exp Ther Med, 22: 1308.（SCI收录，IF 2.447）.............................................................................20

[21] Pan, X., L. Tian, F. Yang, J. Sun, X. Li, N. An, Y.Xing, X. Su, X. Liu, C. Liu, Y. Gao*,and Y. Xing*. 2021. 'Tai Chi as a Therapy of Traditional Chinese Medicine onReducing Blood Pressure: A Systematic Review of Randomized Controlled Trials',Evid Based Complement Alternat Med, 2021: 4094325.（SCI收录，IF 2.629）.....21

[22] Wu, X., T. Zhang, P. Lyu, M. Chen, G. Ni, H. Cheng, G.Xu, X. Li, L. Wang, and H. Shang.2021. 'Traditional Chinese Medication Qiliqiangxin Attenuates DiabeticCardiomyopathy via Activating PPARgamma', Front Cardiovasc Med, 8: 698056.（SCI收录，IF 2.16）..............................................................................................22

[23]Yang, X., G. Li^#, M. Guan^#, A.Bapat^#, Q. Dai, C. Zhong, T. Yang, C. Luo, N. An, W. Liu, F. Yang,H. Pan, P. Wang, Y. Gao, Y. Gong, S.Das*, H. Shang*, and Y. Xing*. 2021.'Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: ASystematic Review and Meta-Analysis', Front Cardiovasc Med, 8: 651269.（SCI收录，IF 2.16）.............................................................................................................23

2.脑血管病方向

[24] Qin, G., Y. Dong^#,Z. Liu^#, Z. Gong, C. Gao, M. Zheng, M. Tian, Y. He, L. Zhong, and P. Wang*. 2021. 'Shen-Zhi-Ling oralliquid ameliorates cerebral glucose metabolism disorder in early AD via insulinsignal transduction pathway in vivo and in vitro', Chin Med, 16: 128.（SCI收录，IF 5.455）.................................................24

[25] Zheng, M., Z. Liu,L. Mana, G. Qin, S. Huang, Z. Gong, M. Tian, Y. He, and P. Wang*. 2021. 'Shenzhiling oral liquid protects the myelin sheathagainst Alzheimer's disease through the PI3K/Akt-mTOR pathway', JEthnopharmacol, 278: 114264.（SCI收录，IF 4.36）.........................................................................................................25

[26]Zhou, D., K. Cen, W. Liu, F. Liu, R. Liu, Y. Sun, Y.Zhao, J. Chang*, and L. Zhu*. 2021.'Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibitingthe ROCKII pathway, in vitro and in vivo', J Ethnopharmacol, 272: 113943.（SCI收录，IF 4.36）............................................................................................................26

[27] Qin, G., Y. Wang^#, Z. Liu^#, L. Mana, S.Huang, and P. Wang*. 2021. 'Shenzhiling oral solution promotes myelinrepair through PI3K/Akt-mTOR pathway in STZ-induced SAD mice', 3 Biotech, 11:361.（SCI收录，IF 2.406）..............................27

[28] Zheng M, Wang P*. Role ofinsulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway inAlzheimer's disease. 3 Biotech 2021, 11(4): 179. （SCI收录，IF 2.406）........................................................................................................28

[29] Zhou, D., L. Xie, X. Shi, F. Liu, S. Wu, S. Zhang, R.Liu, J. Chang, and L. Zhu*.. 2021.'A meta-analysis of the clinical efficacy of Tanreqing injection combined withantibiotics vs antibiotics alone for treating pulmonary infection secondary tointracerebral hemorrhage', Medicine (Baltimore), 100: e24905.（SCI收录，IF 1.889）........................................................................................................................29

[30] YongXin Ru,XueBinZhang,ShuXu Dong,Yongqiang Zhang,Ying Li,Jing Liu,YingDai Gao,HongCai Shang*,Eyden Brian.Histopathological and ultrastructural study of carotid atherosclerotic plaques:a study of four cases.[J]. Ultrastructural pathology,2021,45(4-5). （SCI收录，IF1.094）....................................................30

[31] J Chen，X Wei，Q Zhang，H Xia，G Xia，Y Wu，S Lin*，H Shang* Progress of ubiquitin-proteasome system in the pathophysiology ofheart failure and the intervention of traditional Chinese medicine.TMR Modern Herbal Medicine.........................................................................................................................31

3. 肾脏病、内分泌、风湿免疫方向

[32] Gao, Z.^#,X. Xu^#, Y. Li, K. Sun, M. Yang, Q. Zhang, S. Wang, Y. Lin, L. Lou, A. Wu,W. Liu*, and B.Nie*. 2021. 'Mechanistic Insight into PPARgamma and Tregs in AtheroscleroticImmune Inflammation', Front Pharmacol, 12: 750078.（SCI收录，IF 5.81）....................................................................................................................32

[33] Zhang, H., J. Liu^#, P. Zhang^#,D. Li^#, G. Feng, M. Huandike, S. Sun, L. Chai*, and J.Zhou*. 2021. 'Herbal Formula Longteng Decoction Promotes the Regression ofSynovial Inflammation in Collagen-Induced Arthritis Mice by Regulating Type 2Innate Lymphocytes', Front Pharmacol, 12: 778845.（SCI收录，IF.5.811）...................................................................................................................33

[34] Li, J., Q. Sun^#, C. Zheng, C. Bai, C. Liu,X. Zhao, P. Deng, L. Chai*, and Y. Jia*. 2021. 'Lipoxin A4-Mediated p38MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis',Biochem Genet, 59: 346-65.（SCI收录，IF 1.89）..........................................................................................................................34

4. 循证评价方向

[35]Sun, Y.*, Y.Liu^*, B. Liu, K. Zhou, Z. Yue, W. Zhang, W. Fu, J. Yang, N. Li,L. He, Z. Zang, T. Su, J. Fang, Y. Ding, Z. Qin, H. Song, H. Hu, H. Zhao, Q.Mo, J. Zhou, J. Wu, X. Liu, W. Wang, R. Pang, H. Chen, X. Wang, and Z. Liu.2021. 'Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic PainSyndrome : A Randomized Trial', Ann Intern Med, 174: 1357-66.（SCI收录，IF25.391）................................35

[36]Chen, Z., Y. Jiang, X. Zhang, R. Zheng, R. Qiu,Y. Sun, C. Zhao, and H. Shang*. 2022. 'ResNet18DNN: prediction approachof drug-induced liver injury by deep neural network with ResNet18', BriefBioinform, 23.（SCI收录，IF 11.622）...................36

[37] Wei, X*., X. Wu,Z. Cheng, Q. Wu, C. Cao, X. Xu*, and H.Shang. 2022. 'Botanical drugs: a new strategy for structure-based targetprediction', Brief Bioinform, 23.（SCI收录，IF 11.622）.....................................................................................37

[38] Zhang, X., L. Zhang, W. Xiong, X. Wang, X. Zhou, C.Zhao, G. Tian, H. Shang, T. Wu*, J.Miao, and Z. Bian*. 2021. 'Assessment of the reporting quality of randomisedcontrolled trials of massage', Chin Med, 16: 64.（SCI收录，IF 5.81）..........................................................................................................................38

[39] Sun, X., L. Li^#,Y. Liu, W. Wang, M. Yao, J. Tan, Y. Ren, K. Deng, Y. Ma, Y. Wang, J. Chen, W.Huang, Q. Xia, Y. Li, and H. Shang*.2021. 'Assessing Clinical Effects of Traditional Chinese MedicineInterventions: Moving Beyond Randomized Controlled Trials', Front Pharmacol,12: 713071.（SCI收录，IF 5.455）................................39

[40] Ge, L., H. Zhu, Q.Wang, M. Li, J. Cai, Y. Chen, Y. Chen, B. Ding, B. Fang, Y. Fei, J. Feng, X.Guo, R. Jiang, Y. Jiang, G. Li, X. Li, X. Li, Q. Liang, J. Liu, J. Liu, Q. Liu,S. Liu, Y. Lu, Q. Miao, W. Qi, H. Shang, L. Shi, X. Tan, X. Tang, X.Wang, X. Wang, W. Xia, K. Yang, L. Yang, Y. Ye, Q. Zhou, H. Zhang, J. Zhang, Z.Zhang, Z. Zhang, X. Zou, J. Li, and D. Wu. 2021. 'Integrating Chinese andwestern medicine for COVID-19: A living evidence-based guideline (version 1)',J Evid Based Med, 14: 313-32.（SCI收录，IF 5.267）......................................................................................40

[41]Tian, G., C. Zhao, X. Zhang, W. Mu, Y. Jiang, X. Wei,M. Zhao, Z. Shi, Y. Jin, J. Si, J. Wang, J. Hu, M. Guan, R. Qiu, C. Zhong, M.Li, Y. Sun, Z. Chen, L. You, J. Li, and H.Shang*. 2021. 'Evidence-based traditional Chinese medicine research: Twodecades of development, its impact, and breakthrough', J Evid Based Med, 14:65-74.

（SCI收录，IF 5.267）..........................................................................................41

[42]Hu Jiayuan,QiuRuijin^#,Li Chengyu,Li Min,Dai Qianqian,Chen Shiqi,Zhao Chen,ShangHongcai. Problems with the outcome measures in randomized controlled trials oftraditional Chinese medicine in treating chronic heart failure caused bycoronary heart disease: a systematic review[J]. BMC Complementary Medicine andTherapies,2021,21(1).（SCI收录，IF3.659）........................................................42

[43] Chen, J., J. Y.Li, G. H. Tian, R. J. Qiu, X. Q. Zhao, X. S. Di, Q. M. Yuan, S. W. Long,Y. Ran, Y. S. Jia*, and H. C. Shang*. 2021. 'A national snapshot of theimpact of clinical depression on post-surgical pain and adverse outcomes afteranterior cervical discectomy and fusion for cervical myelopathy andradiculopathy: 10-year results from the US Nationwide Inpatient Sample', PLoSOne, 16: e0258517.（SCI收录，IF3.24）.............................................................................................................43

[44] Qiu, R. J., M. Li, J. Y.Hu, J. Chen*, and H. C. Shang*. 2021. 'Methods fordevelopment of a core outcome set for clinical trials integrating traditionalChinese medicine and Western medicine', J Integr Med, 19: 389-94.（SCI收录，IF 3.034）.........................................................................................................................44

[45] Sun, Y., Y. Liu^#, H. Chen, Y. Yan*,and Z. Liu*. 2021. 'Electroacupuncture for stress-predominant mixed urinaryincontinence: a protocol for a three-armed randomised controlled trial', BMJOpen, 11: e038452.（SCI收录，IF 2.692）.........................................................................................................................45

[46]He, F.^#, W. Su^#, R. Wu, H. Li,L. Lou, A. Wu, L. Xie, Y. Du*, and S. Wu*. 2021. 'The effect of coldexposure on serum cholesterol is dependent upon ApoE', J Therm Biol, 99:102972.（SCI收录，IF 2.9）...................................................................46

[47] Zhao, M. Z., C. Zhao, S. S. Tu, X. X. Wei, and H. C. Shang*. 2021. 'Evaluating themethodology of studies conducted during the global COVID-19 pandemic: Asystematic review of randomized controlled trials', J Integr Med, 19: 317-26.（SCI收录，IF2.681）............................................................................................................47

[48] Zeng, Z., M. Li, Y. Zeng, J. Zhang, Y. Zhao, Y. Lin,R. Qiu*, D. S. Zhang*, and H. C. Shang*. 2021. 'Potential AcupointPrescriptions and Outcome Reporting for Acupuncture in Atopic Eczema: A ScopingReview', Evid Based Complement Alternat Med, 2021: 9994824.（SCI收录，IF2.629）.........................................................48

[49] Li, B., Y. Lin, B. Nie, G. Zhao, X. Zhang, M. Zhu, J.Hu, P. Huang, S. Feng, R. Qiu, G. Tian, S. Zhang, and H. Shang*. 2021. 'Systematic review and pathway enrichment analysisof Chinese medicine in preventing recurrence and improving prognosis ofcholelithiasis after gallbladder-preserving lithotripsy', Ann Palliat Med, 10:12985-3001.（SCI收录，IF2.465）................................49

[50] Li, C. Y., Y. L. Chen, J. Y. Hu, M. Li, X. Y. Zhang,Y. Sun, R. Zheng, S. Q. Chen, S. J. Han, T. M. He, and H. C. Shang*. 2021. 'Status Quo and Analysis of the CardiovascularClinical Practice Guidelines/Expert Consensuses of Chinese and IntegrativeMedicine: A Systematic Review', Chin J Integr Med, 27: 54-61.（SCI收录，IF 1.978）...........................................................................................................50

[51]Zhang, X., C. Zhao^#, H. Zhang^#,W. Liu, J. Zhang, Z. Chen, L. You, Y. Wu, K. Zhou, L. Zhang, Y. Liu*, J. Chen*,and H. Shang*. 2021. 'DyspneaMeasurement in Acute Heart Failure: A Systematic Review and Evidence Map ofRandomized Controlled Trials', Front Med (Lausanne), 8: 728772.（SCI收录，IF 0.649）.........................................................................................................................51

5. 中药药理及作用机制方向

[52] Zuo, R., L. F. Ye^#, Y. Huang, Z. Q. Song^#,L. Wang^#, H. Zhi, M. Y. Zhang, J. Y. Li, L. Zhu, W. J. Xiao, H.C. Shang*, Y. Zhang,* R. R. He*, and Y. Chen*. 2021. 'Hepatic smallextracellular vesicles promote microvascular endothelial hyperpermeabilityduring NAFLD via novel-miRNA-7', J Nanobiotechnology, 19: 396.（SCI收录，IF10.435）......................................................................................................................52

[53]Xia, H., Y. Liu^#,G. Xia, Y. Liu*, S. Lin*. and L.Guo*. 2021. 'Novel Isoquinoline Alkaloid Litcubanine A - A PotentialAnti-Inflammatory Candidate', Front Immunol, 12: 685556.（SCI收录，IF 7.56）.................................................................................53

[54] He, S., F. Lyu,L. Lou, L. Liu, S. Li, J. Jakowitsch, and Y. Ma*. 2021. 'Anti-tumoractivities of Panax quinquefolius saponins and potential biomarkers in prostatecancer', J Ginseng Res, 45: 273-86.（SCI收录，IF 6.046）.................................................54

[55]Wang, C., M. Huandike^#, Y. Yang^#,,H. Zhang^#,, G. Feng, X. Meng, P. Zhang, J. Liu, J. Li*, and L.Chai*. 2021. 'Glycosides of Caulis Lonicerae inhibits the inflammatoryproliferation of IL-1beta-mediated fibroblast-like synovial cells coculturedwith lymphocytes', Phytother Res.（SCI收录，IF 5.882）.........................................................................................................................55

[56]Li, Y. S., J. Zhang, G. H. Tian*, H. C. Shang, and H.B. Tang*. 2021. 'Kirenol, darutoside and hesperidin contribute to theanti-inflammatory and analgesic activities of Siegesbeckia pubescens makino byinhibiting COX-2 expression and inflammatory cell infiltration', JEthnopharmacol, 268: 113547.（SCI收录，IF 4.36）.................56

[57] Li, C., P. Wang^#,M. Li, R. Zheng, S. Chen, S. Liu, Z. Feng, Y. Yao, and H. Shang*. 2021. 'The current evidence for the treatment of sepsiswith Xuebijing injection: Bioactive constituents, findings of clinical studiesand potential mechanisms', J Ethnopharmacol, 265: 113301.（SCI收录，IF4.36）.............................................57

[58]Xia, G. Y., D. J. Fang^#,L. Y. Wang, H. Xia, Y. N. Wang, H. C. Shang*, and S. Lin*. 2022. '13,13a-seco-protoberberines from the tubers ofCorydalis yanhusuo and their anti-inflammatory activity', Phytochemistry, 194:113023.（SCI收录，IF 4.072）.........................................................................................................................58

[59]Xia, H., G. Y. Xia, L. Y. Wang, M.Wang, Y. N. Wang, P. C. Lin, and S. Lin*.2021. 'Bioactive sesquineolignans from the twigs of Litsea cubeba', Chin J NatMed, 19: 796-800.（SCI收录，IF 3.0)..............................................................................59

[60]Xia, H., J. F. Zhang, L.Y. Wang, G. Y. Xia, Y. N. Wang, Y. Z. Wu, P. C. Lin, L. Xiong, and S. Lin*.. 2022. 'Bioactive neolignansand lignans from the roots of Paeonia lactiflora', Chin J Nat Med, 20: 210-14.（SCI收录，IF 3.0）...................................60

备注：#：共同第一作者；*：通讯作者

中 文 文 章

1. 心血管病方向

[1] 邱瑞瑾,孙杨,韩松洁,何天麦,钟长鸣,关曼柯,胡嘉元,李敏,陈静, 商洪才^*.非瓣膜性房颤中医核心证候指标集的构建[J].中国循证医学杂志,2021,21(12):1480-1488.....................................................................................61

[2] 刘珂珂,吕梦,纪晓迪,娄利霞,赵一舟,吴爱明^*.稳心颗粒调控内质网应激途径抑制心梗大鼠心肌凋亡的机制[J].中国实验方剂学杂志,2021,27(03):56-62.DOI:10.13422/j.cnki.syfjx.20210337........................................................62

[3] 周亚滨,夏兆晨,张晶晶,王卓溪,刘影哲, 商洪才^*.中药注射液治疗心力衰竭疗效研究的网状Meta分析[J].中国循证医学杂志,2021,21(09):1067-1074.......................................................................................................................63

[4] 万思琦,张晓雨,张晶晶,郑蕊,邱瑞瑾,赵晨, 商洪才^*.中西医结合防治冠心病方案的循证优化设计与实施要点[J].中西医结合心脑血管病杂志,2021,19(17):2865-2870............................................................................................................................64

[5] 王曼曼,贾冬冬,吴丹丹,高毅洁,杨睿,国倩倩,张冬梅^*.血府逐瘀胶囊治疗血脂异常有效性及安全性的Meta分析[J].中国中医药信息杂志,2021,28(11):34-39.DOI:10.19879/j.cnki.1005-5304.202012003............65

[6] 邱瑞瑾,雷翔,陈静, 商洪才^*.基于核心指标集及模糊综合评价法探索冠心病心绞痛中药品种筛选方法[J].中国中药杂志,2021,47(01):265-270.DOI:10.19540/j.cnki.cjcmm.20210729.501.......................................................66

[7] 钟长鸣,石兆峰,代倩倩,赵晨, 商洪才^*.复方丹参滴丸联合西药常规治疗对急性心肌梗死经皮冠状动脉介入术后炎症因子和心功能影响的系统评价[J].中国循证医学杂志,2021,21(06):662-668.............................................................................67

[8] 尤良震,潘海娥,代倩倩,钟长鸣,魏旭煦,蒋寅,石兆峰,张晓雨,赵晨, 商洪才^*.糖尿病心脏病中医病机述要[J].中医杂志,2021,62(12):1013-1019.DOI:10.13288/j.11-2166/r.2021.12.001.....................................................................................................68

[9] 李慧敏,熊兴江,胡瑞学,于丹丹,赵晖,廖星,杨伟,商洪才^*.中医药治疗急性心肌梗死随机对照试验结局指标的现状分析[J].中医杂志,2021,62(05):405-413.DOI:10.13288/j.11-2166/r.2021.05.009....................................................69

[10] 刘珂珂,王帅,吴爱明^*,侯雅竹,娄利霞,吕梦,张冬梅,商洪才.芪丹利心丸减轻心肌梗死大鼠心肌凋亡的机制研究[J].中西医结合心脑血管病杂志,2021,19(03):423-427......................................................................................70

[11] 袁慧婵,沈晓旭,张夏天,邱瑞瑾,张晓雨,李洁白,王博约,杨倩,商洪才^*.麝香保心丸治疗冠心病心绞痛的系统评价再评价[J].中国中医急症,2021,30(02):218 -221+256..............................................................................71

[12]马明玥,卫晓红,商洪才,钟长鸣,潘海娥,代倩倩,王宇红^*.高脂血症加重慢性心力衰竭大鼠抑郁样行为的作用机制[J].北京中医药大学学报,2021,44(11):1020-1028...................................................................................72

2. 脑血管病方向

[13] 王席玲,段永伟,朱陵群^*,刘卫红.扶正祛邪方联合更昔洛韦对病毒性脑炎疗效、神经功能与脑血流的作用[J].世界中医药,2021,16(13):2015-2018............................................................................................................................73

[14] 王丽琴,孙逸坤,王晓峰,李媛媛,宋珂,刘浩琦,常静玲,高永红^*.醒脑静注射液对大鼠脑出血模型血脑屏障通透性及相关蛋白的影响[J].环球中医药,2021,14(06):993-999.........................................................................................74

[15]刘蕊嘉,于旭东,徐薇薇,阎明源,王海若,朱陵群^*.从阳虚辨证治失眠[J].海南医学院学报,2021,27(08):619-621+625. 20200608.001.…………………...75

[16]孙逸坤,吴丽君,李媛媛,刘浩琦,安娜,宋珂,张华, 高永红^*.醒脑静注射液对大鼠脑缺血急性期半暗带转化的影响[J].海南医学院学报,2021,27(23):1761-1767.DOI:10.13210/j.cnki.jhmu.20210616.001..........76

[17]马喆,王思锦,高永红,程炜婷,巩卓彦,孙逸坤,薛程元,金秋硕,高颖,娄利霞^*.松龄血脉康胶囊对大鼠脑缺血再灌注损伤内质网应激凋亡相关蛋白的影响[J].湖南中医药大学学报,2021,41(05):685-690.........................................................77

[18] 巩卓彦,吴艺琼,黄帅阳,刘珍洪,秦高凤,王蓬文^*.基于突触和突触蛋白探讨复方金思维对拟散发性阿尔茨海默病小鼠早期突触传递和功能的影响[J].环球中医药,2021,14(01):19-25...............................................................................78

[19] 陈莹,常静玲,李新龙,刘岩,张晶晶,张学成,代恒恒,商洪才^*.基于CNKI的近10年中医药治疗缺血性脑卒中研究的可视化分析[J].时珍国医国药,2021,32(11):2803-2806....................................................................................79

[20] 阎明源,王海若,张海艳,刘蕊嘉,刘凤智,高梦霞,周东蕊,常静玲,朱陵群^*.血塞通联合依达拉奉对急性脑梗死患者血液流变学影响的meta分析[J].海南医学院学报,2021,27(23):1800-1807.20210111.001............................................80

[21] 刘浩琦,张涵莱,李媛媛,宋珂,安娜,王丽琴,孙逸坤,高永红^*.基于GC-MS代谢组学的醒脑静注射液干预脑缺血再灌注大鼠模型的作用机制研究[J].海南医学院学报,2022,28(08):572-578.20210824.008................................................81

3. 循证评价方向

[22] 邱瑞瑾,孙杨,钟长鸣,李敏,胡嘉元,赵晨,陈静,商洪才^*.中医核心证候指标集的构建思路[J].中国循证医学杂志,2021,21(11):1353-1357.....................................82

[23] 张学成,刘岩,张晶晶,陈莹,代恒恒,万思琦,关之玥,胡明智,商洪才^*.急性心力衰竭患者30天再住院率：基于真实世界研究与随机对照试验比较的Meta分析[J].中国循证医学杂志,2021,21(10):1203-1210...........................................................................................................................83

[24] 黄忠营,孙卫强,邓宏勇,赖佳琪,刘少南,杨丽虹,郭新峰^*,吴大嵘,商洪才.中医随机对照试验元数据完整性的评价[J].中国循证医学杂志,2021,21(10):1211-1218....................................................................................84

[25] 关之玥,刘岩,张晶晶,陈莹,代恒恒,张学成,胡明智,商洪才^*.母方案平台试验设计方法及其在相关领域中的应用[J].中国循证医学杂志,2021,21(08):986-992...........................................................................................................................85

[26] 荣红国,邢叶一祎,董玥,夏如玉,商洪才,刘建平,费宇彤^*.政策工具视角下我国抗菌药物合理用药政策研究[J].中国卫生政策研究,2021,14(08):45-51...............................................................................................................................86

[27] 魏旭煦,关曼柯,石兆峰,尤良震,蒋寅,赵晨^*,商洪才^*.中医临床试验证据个体适用性评价方法的探索构建[J].中国循证医学杂志,2021,21(07):858-862.............................................................................................................................87

[28] 陈昭,郑蕊,张晓雨,邱瑞瑾,潘海娥,孙杨,赵晨,田贵华,商洪才^*.基于斑马鱼模型探讨血必净注射液与3种抗生素并用对肝损伤的影响[J].药物评价研究,2021,44(07):1385-1391...................................................................................88

[29] 李新龙,陈雅丹,刘长英,胡烨胤,刘岩,张冬梅,田贵华,商洪才^*.1997-2019年国家自然科学基金中医内科学领域研究前沿的可视化分析[J].中医杂志,2021,62(13):1120-1125.DOI:10.13288/j.11-2166/r.2021.13.005...........89

[30] 林繄依,赵晨,石兆峰,宋珂,赵赛,马彬,李博,田贵华,商洪才^*,聂波^*.四妙勇安汤干预动脉粥样硬化模型整体动物实验的系统评价[J].中国循证医学杂志,2021,21(05):559-565.......................................................................................90

[31] 胡嘉元,李江,翟静波,李博,田金徽,马彬,杨克虎,代敏,田贵华,商洪才^*,张弛,段玉婷,卞兆祥^*.中医药单病例随机对照试验报告规范（中医药CENT）:CENT声明的扩展、说明与详述[J].中国循证医学杂志,2021,21(03):338-346........................................................................................91

[32] 蒋寅,刘岩,商洪才^*,张弛,段玉婷,卞兆祥^*,Eldridge SM,Chan CL,Campbell MJ.CONSORT 2010声明：针对随机先导性和可行性试验的扩展[J].中国循证医学杂志,2021,21(03):313-337............................................................92

[33] 韩晟,赵熙子,史录文,林丽开,李大魁,陈凯先,宣利江,马传江,马海英,方唯一,王丽霞,文爱东,付秀娟,左燕,刘小玲,刘向红,刘国强,朱珠,陈万生,陈维红,吴方建,吴玉波,吴晖,张伟,张毕奎,林慧,周国华,欧阳荣,胡元会,姜明燕,赵春景,贾乐川,晋月萍,唐洪梅,曹俊岭,梁春,商洪才,董占军,董吁钢,翟所迪.注射用丹参多酚酸盐的临床应用综合评价[J].中国药学杂志,2021,56(06):507-514..........................................................................................................................93

[34] 王艳萍,商洪才,王飞,李书晴,颜冬梅,周旭^*.热敏灸治疗带状疱疹后神经痛疗效与安全性的系统评价和Meta分析[J].光明中医,2021,36(05):675-680...........................................................................................................................94

[35] 韩晟,赵熙子,史录文,林丽开,李大魁,陈凯先,宣利江,马传江,马海英,方唯一,王丽霞,文爱东,付秀娟,左燕,刘小玲,刘向红,刘国强,朱珠,陈万生,陈维红,吴方建,吴玉波,吴晖,张伟,张毕奎,林慧,周国华,欧阳荣,胡元会,姜明燕,赵春景,贾乐川,晋月萍,唐洪梅,曹俊岭,梁春,商洪才,董占军,董吁钢,翟所迪.注射用丹参多酚酸盐的药学综合评价[J].中国药学杂志,2021,56(05):422-428............................................................................................................................95

[36] 王琪,后亮瑛,朱鸿飞,栗梦婷,张迁,周奇,陈耀龙,杨克虎,商洪才,郭新峰,吴大嵘^*,葛龙^*.《中西医结合预防与治疗COVID-19的动态循证指南》计划书[J].中国中药杂志,2021,46(19):5117-5122.DOI:10.19540/j.cnki.cjcmm.20210224.501.............................................96

[37] 赵晨,付姝菲,段玉婷,张弛,商洪才,卞兆祥^*.CONSORT声明：在牙科矫正临床试验中的扩展与应用[J].中国循证医学杂志,2021,21(02):219-230.............................................................................................................................97

[38] 魏旭煦,刘岩,胡嘉元,蒋寅,商洪才,张弛,段玉婷,卞兆祥^*.多臂平行对照随机临床试验报告规范：CONSORT 2010声明扩展版[J].中国循证医学杂志,2021,21(02):231-240.......................................................................................98

[39] 王家莹,付姝菲,段玉婷,张弛,商洪才,卞兆祥^*.卫生保健仿真研究报告规范：基于CONSORT和STROBE声明的扩展[J].中国循证医学杂志,2021,21(02):241-248.......................................................................................99

[40] 陈耀龙^*,罗旭飞,史乾灵,吕萌,周奇,王健健,杨楠,高东平,杨书,商洪才,杨克虎.人工智能如何改变指南的未来[J].协和医学杂志,2021,12(01):114-121.

....................................................................................................................................100

[41] 田然,林伟青,段玉婷,卞兆祥^*,张弛,商洪才.草药干预措施随机对照试验报告：CONSORT扩展声明[J].中国循证医学杂志,2021,21(01):97-99............................................................................................................................101

[42] 田然,林伟青,段玉婷,商洪才,张弛,卞兆祥^*.报告草药干预措施随机对照试验的建议：解释和说明[J].中国循证医学杂志,2021,21(01):100-110...........................................................................................................................102

[43] 尤良震,赵晨,张晓雨,商洪才,王永炎.病络理论下泛血管疾病中西医结合防治理论基础及实施思路[J/OL].中国中西医结合杂志:1-4[2022-05-10].20211203.1327.002.html.......................................................................................103

[44] 崔鹤蓉,张晓雨,尤良震,郑蕊,陈昭,蒋寅,张晶晶,商洪才^*.临床“有毒”中药多元整合证据评价与预测方法的建立[J].中国中药杂志,2022,47(08):2266-2272.DOI:10.19540/j.cnki.cjcmm.20211129.601....104

[45] 韩松洁,钟长鸣,商洪才^*,田贵华^*.针刺治疗带状疱疹临床有效性及安全性的Meta分析[J].世界科学技术-中医药现代化,2020,22(09):3374-3383.........................................................................................................................105

[46] 杨衍涛,郑明福,王健健,钱昌丽,高姗,赵怡迪,陈耀龙^*,商洪才^*.中医药临床实践指南和专家共识引用系统评价/Meta分析现况调查[J].中国循证医学杂志,2021,21(01):83-89.........................................................................................106

4. 中药药理及作用机制方向

[47] 王淑琪,孙克寒,陈菲,高照,林繄依,杨漫芳,许心蕊,聂波^*.基于网络药理学探讨“金银花-玄参”药对治疗动脉粥样硬化的分子机制[J].中国医药导报,2021,18(15):21-26+197...................................................................................107

[48] 蒋锋利,蔡松,任士杰,孙文丽,张晶,赵明镜,张立山^*.大黄?虫丸对TGF-β_1干预后A549细胞增殖的影响[J].吉林中医药,2021,41(01):89-93.DOI:10.13463/j.cnki.jlzyy.2021.01.025..................................................108

[49] 蒋锋利,黄茂,蔡松,任士杰,孙文丽,张晶,赵明镜,张立山^*.大黄■虫丸对TGF-β1干预后A549细胞EMT与Smad2及Collagen Ⅰ表达情况的影响[J].辽宁中医杂志,2021,48(08):225-228+253.DOI:10.13192/j.issn.1000-1719.2021.08.064.................................................................................................109

[50] 李晓斌,曹旭,糟小宾,李硕,陈贺宁,朱顺,李小科^*,叶永安^*.基于网络药理学及分子对接研究苦参治疗慢性乙型肝炎的作用机制[J].世界科学技术-中医药现代化,2021,23(06):1737-1744..........................................................................110

[51] 徐冰,角加,聂波^*.八味沉香散对缺血再灌注损伤心肌细胞SOD、MDA和凋亡影响的研究[J].吉林中医药,2021,41(03):376-380.DOI:10.13463/j.cnki.jlzyy.2021.03.024...............................................111

5. 药物分析方向

[52] 孙彦斌,夏桂阳^*,夏欢,武玉卓,王玲燕,林生^*.赤芍内生真菌Colletotrichum capsici中的1个新酚酸酯成分[J].中国中药杂志,2021,46(11):2837-2842.DOI:10.19540/j.cnki.cjcmm.20210402.20.......112

[53]方冬杰,夏桂阳^*,王玲燕,夏欢,孙彦斌,林生^*.醋制延胡索中一个新的原小檗碱型二聚体生物碱[J].药学学报,2021,56(04):1096-1099.DOI:10.16438/j.0513-4870.2021-0121.....................................................113

[54] 孙克寒,杨会,王淑琪,王春国,杨漫芳,高照,许心蕊, 聂波^*.基于UPLC-LTQ-Orbitrap-MS法分析四妙勇安汤的化学成分[J/OL].中国中药杂志:1-10[2022-05-08].DOI:10.19540/j.cnki.cjcmm.20210823.303........................114

6. 中医理论方法

[55] 白云绮,李慧,宋珂,王淑琪,高照,孙克寒,金秋硕,娄利霞,吴爱明,吴圣贤,聂波^*.ApoE~(-/-)小鼠动脉粥样硬化模型的中医证型[J].世界中医药,2021,16(01):71-76...........................................................................................115

[56] 张迪,王文雅,许宗颖,张冬梅,王旭,陈萌^*.从经方方元解读小青龙汤的组方内涵[J].吉林中医药,2021,41(08):1094-1097.DOI:10.13463/j.cnki.jlzyy.2021.08.030..............................................116

[57] 曹旭,李小科,糟小宾,杨先照,张嘉鑫,李志国,杜宏波,叶永安^*. 乙型肝炎病毒相关肝细胞癌的关键基因筛选及临床意义[J]. 世界科学技术-中医药现代化,2021,06:1753-1772.........................................................................................117

[58] 王耀献,孙卫卫^*,刘伟敬,王珍.辨机论治诊疗模式及其临床应用意义[J].中医杂志,2021,62(23):2025-2031.2021.23.001……………………………..118

[59] 毛炜,余仁欢,刘文军,方敬爱^*,刘伟敬^*,刘玉宁^*.从痰论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2021,22(11):1032-1034.........................................................................................................................119

[60] 姜玉华,蔡雨孜,娄文娇,刘玉宁,刘伟敬^*.刘伟敬从风-虚-瘀论治肾性血尿思路探析[J].辽宁中医杂志,2021,48(10):28-31.DOI:10.13192/j.issn.1000-1719.2021.10.008...................................................................................................120

[61] 刘光珍,赵文景,魏连波,方敬爱,刘伟敬^*,刘玉宁^*.从瘀论治慢性肾脏病的思路与方法[J].中国中西医结合肾病杂志,2021,22(07):656-658...........................................................................................................................121

[62] 周思敏,黄为钧,姚魁武^*.从肺论治高血压病临床实践[J].北京中医药,2021,40(06):584-586.DOI:10.16025/j.1674-1307.2021.06.006...........122

[63] 刘宝利,钟逸斐,刘伟敬,王明,杨波,陈洪宇,毛志国,周亦伦,孙芳,芮宏亮,段亚娟,刘文虎,杨洪涛^*,张霄潇^*.中医药临床优势病种探讨——膜性肾病[J].中国实验方剂学杂志,2021,27(16):185-190.DOI:10.13422/j.cnki.syfjx.20211691.......................................................123

[64] 戴恩来,李小会,余仁欢,刘伟敬^*,方敬爱^*,刘玉宁^*.从湿热论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2021,22(05):468-470………...........124

[65] 符馨文,王娅辉,刘伟敬,刘玉宁^*.刘玉宁教授运用中医治疗Fabry病的思路与方法[J].中国中西医结合肾病杂志,2021,22(05):377-379..........................125

[66] 张帆,刘伟敬,郑慧娟,郭敬,郭小乐,艾思南,刘相均,申玥,王耀献^*.糖尿病肾病之六经辨证初探[J].环球中医药,2021,14(05):835-840...........................126

[67] 姜玉华,蔡雨孜,娄文娇,刘玉宁,刘伟敬^*.刘伟敬教授从风-虚-瘀论治肾性血尿思路探析[J/OL].辽宁中医杂志:1-9[2022-05-08]. 20210427.1058.022.html.....................................................................................127

[68] 艾思南,王珍,郑慧娟,郭敬,高亚斌,刘相均,张帆,申玥,王耀献^*.基于“低氧”机制探讨糖尿病肾脏病“壮火食气”的科学内涵[J].环球中医药,2021,14(04):602-605.....................................................................................128

[69] 侠晨辉,刘玉宁,朱泽兵,刘伟敬^*.基于相关指南浅析糖尿病肾脏病高血压中医分期分型论治[J].新中医,2021,53(05):199-204.DOI:10.13457/j.cnki.jncm.2021.05.053. ................................................129

[70] 郭立中,谢院生,方敬爱^*,刘伟敬^*,刘玉宁^*.慢性肾脏病肾性贫血的中西医诊断与治疗[J].中国中西医结合肾病杂志,2021,22(01):92-94. ....................130

[71] 倪博然,赵进喜^*,黄为钧,王世东.基于视觉模拟评分法探究中医临床疗效评价新方法[J].中华中医药杂志,2021,36(01):288-292..................................131

7. 肾脏病、内分泌、风湿免疫方向

[72] 陈宇,李丽娜,苏冠旬,王世东^*,赵进喜,黄为钧,赵博旭,王淑艳,陈小愚,李哲.基于p38 MAPK信号转导通路探究从风论治法对高糖诱导人肾小球系膜细胞免疫炎症损伤的影响[J].中华中医药杂志,2021,36(10):6141-6145..............132

[73] 鲁盈,郭兆安,樊均明,方敬爱^*,刘伟敬^*,刘玉宁^*.从微型癥积论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2021,22(09):845-846..................133

[74] 艾思南,朱泽兵,郑慧娟,田蕾,王耀献^*,刘伟敬^*.基于网络药理学分析当归补血汤治疗糖尿病肾脏病的内在机制[J].世界中医药,2021,16(15):2254-2260............................................................................................................................134

[75] 艾思南,朱泽兵,郑慧娟,郭敬,田蕾,尹诗卉,王耀献^*,刘伟敬.基于网络药理学分析尿毒清颗粒治疗慢性肾脏病的内在机制[J].中国中西医结合肾病杂志,2021,22(05):409-413+474..............................................................................135

[76] 李延婷,巩勋,姜泉^*,李克嵩,刘蔚翔,翟争,刘岩,张依.气象要素对类风湿关节炎中医证候分布的影响[J].中华中医药杂志,2021,36(01):386-389.......136

[77] 李元,王异玲,杨其文,王莉华,柴立民,周静威^*.北京地区季节对类风湿关节炎发病特点和免疫炎症指标的影响研究[J].江苏中医药,2021,53(12):35-38.DOI:10.19844/j.cnki.1672-397X.2021.12.013............................................137